Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Severe obesity is already a significant problem for many children, especially since obese children often become obese adults.

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...

The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...

The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...

Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...

Children who used the weight loss drug liraglutide in a late-stage trial lost significantly more weight than children who got ...

Liraglutide has been found to safely reduce BMI in children aged 6 to under 12, offering a potential new treatment for pediatric obesity. The obesity medication liraglutide was found to be safe and ...

For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication ...

Liraglutide results in greater reduction in BMI than placebo plus lifestyle intervention for children with obesity ...